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of the intervention under evaluation were found both in the percentage of patients
maintaining total abstinence as well as in the percentage of relapsed patients.
Statistically significant in favor of naltrexone treatment when assessing too such
endpoint as alcohol craving intensity assessment for the NAL/PSY vs ACA/PSY
analysis in a long treatment period and for the NAL/PSY vs PL/PSY analysis in a
short term.Long-term results (52 weeks) of the analysis quoted indicate on a com-
parable clinical efficacy (no statistical significance of results obtained) of the use of
naltrexone and placebo in the group of alcohol-dependent patients undergoing
psychotherapy.The adverse events related to naltrexone treatment are usually
mild and transient. The most frequent ones are: headaches, sleep disorders, anx-
iety, nervousness, gastrointestinal disorders such as abdominal pain, nausea,
vomiting. CONCLUSIONS: Summing up, the results of the analysis carried univo-
cally prove that naltrexone administered in a 50mg dose a day is an effective and
safe drug in the treatment of alcohol dependent patients who additionally undergo
a psychotherapy.
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OBJECTIVES: To assess the impact of adherence to first antidepressant (AD) ther-
apy on risk of AD switching, using nationwide claims database. METHODS: Using
the Korean Health Insurance Review & Assessment Service (HIRA) claims database
(2006-2008), newly diagnosed depression patientswho aged 18-84,withoutmedical
visit due to depression (ICD 10F06.3, F31.3, F31.4, F32, F33, F34.1, F38.1, F41.2)
within 6 months before the first observed prescription of ADs between Jul 2006 to
Jun 2007 (18 months index period), and with at least 3 psychiatric visits within 3
months from index date were identified. ADs were categorized as tricyclic antide-
pressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and new antide-
pressants (NADs). For each AD category, adherence by 90 days post-index period
Medication possession ratio (MPR) was estimated. Switching was defined prescrip-
tion of different class of AD therapy from last AD regimen. Time to first switching
was assessed. Cox proportional hazards model was used to investigate the rela-
tionship between adherence to AD and time to switch. RESULTS: A total of 88,079
patients satisfied the selection criteria, among which mean age of 45.2 years and
67.3% of women.When assessed AD therapywithin 90 days from index date, 31.3%
of the patients prescribed SSRI monotherapy, 16.4% prescribed TCAmonotherapy,
and 15.2% prescribed SSRINAD polytherapy. Overall rate of switching was 38.1%.
When adjusted for age, gender, and AD regimen, patients with higher adherence
(MPR75%) showed lower rate of switching (adjusted OR0.93[95% CI0.91-0.95]).
CONCLUSIONS: Switching AD therapy can be inferred as indicator of insufficient
effectiveness or adverse drug reaction. Improving adherence to AD therapy in
newly diagnosed depression patients is important to prevent the switching AD
therapy afterwards.
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OBJECTIVES: To describe characteristics of patients with schizophrenia receiving
treatment with atypical injectable antipsychotics paliperidone palmitate and ris-
peridone long-acting as compared to other antipsychotics therapy at community
behavioral health organizations (CBHOs) in the United States.METHODS: A longi-
tudinal, noninterventional observational registry, Research and Evaluation of An-
tipsychotic Treatment in Community Behavioral Health Organizations OUTcomes
(REACH OUT) is collecting information on use of paliperidone palmitate, risperi-
done long-acting therapy (LAT), and other antipsychotics by patients with schizo-
phrenia or bipolar type I disorder receiving treatment at CBHOs. Patients are fol-
lowed for 1 year, with assessments at baseline, 6, and 12 months. Sites use a
Web-based data-collection tool to enter patient self-reports, interviewer assess-
ments, and medical record abstractions. RESULTS: At time of analysis, baseline
patient interview data from 114 patients with schizophrenia were collected at 10
sites in the following cohorts: 44% paliperidone palmitate injections, 33% risperi-
done injections, and 23% other antipsychotics. Patients in the paliperidone palmi-
tate or risperidone LAT cohorts were older, on average, than those receiving other
antipsychotics: paliperidone palmitate, 41.2 years; risperidone LAT, 43.0; other an-
tipsychotics, 35.0. Mean age at first psychiatric hospitalization was older for pali-
peridone palmitate (23.1) and risperidone LAT (24.4) than for other antipsychotics
(20.1). Patients receiving the two injectable antipsychotics were more likely to be
male (paliperidone palmitate, 70.0%; risperidone LAT, 73.7%; other antipsychotics,
69.2%) and single/never married (paliperidone palmitate, 78.0%; risperidone LAT,
78.9%; other antipsychotics, 69.2%). Patients treated with atypical antipsychotic
injectionswere less likely to have private health insurance (paliperidone palmitate,
6.0%; risperidone LAT, 0.0%; other antipsychotics, 19.2%) and more likely to have
Medicare (paliperidone palmitate, 60.0%; risperidone LAT, 60.5%; other antipsy-
chotics, 23.1%) or Medicaid (paliperidone palmitate, 82.0%; risperidone LAT, 78.9%;
other antipsychotics, 46.2%). CONCLUSIONS: Results suggest that patients in CB-
HOs receiving paliperidone palmitate and risperidone injections may differ from
patients receiving other antipsychotics io sociodemographics.
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OBJECTIVES: Anticholinergic medications, though frequently used in the elderly
population, are associated with cognitive impairment and use of these agents is a
concern in dementia patients. This study examined the prevalence and predictors
of anticholinergic prescribing in elderly outpatients with dementia. METHODS:
Data from 2006–2007 National Ambulatory Medical Care Survey (NAMCS) and the
outpatient National Hospital Ambulatory Medical Care Survey (NHAMCS) were
combined to analyze elderly (65 years or older) patient visits for dementia (ICD-
9-CM codes-290.XX, 291.2, 294.XX, 331.XX, 046.1 and 046.3). Anticholinergic drugs
were identified using a preexisting scale, the Anticholinergic Drug Scale (ADS),
which classified anticholinergic drugs into four levels in increasing order of their
anticholinergic activity. Descriptive analysis was used to evaluate prevalence pat-
terns and multiple logistic regression was conducted to examine the factors asso-
ciated with prescribing of medications with marked anticholinergic activity (Level
2 or Level 3). RESULTS: According to the 2006-2007 NAMCS and NHAMCS data,
there were a total of 6.8 million (95% Confidence Interval (CI) 5.27-8.44 million,
0.32%) ambulatory care visits for dementia. Nearly 43% (95% CI 35.24%-50.48%) of
all elderly dementia patient visits involved prescribing of at least one anticholin-
ergic drug; 36.76% of the above visits involved Level 1 medications, 10.85% of visits
involved Level 2 or Level 3 medications. While age (75-84 years; Odds Ratio (OR)
0.26, 95% CI0.08-0.85) and acetylcholine esterase inhibitor use (OR 0.21, 95% CI
0.07-0.65) increased the likelihood of prescribing medications with marked anti-
cholinergic activity, total number of medications prescribed also (OR 1.41, 95% CI:
1.81-1.67) increased the likelihood of these prescriptions.CONCLUSIONS:Over 10%
of elderly dementia visits involved prescribing of medications with marked anti-
cholinergic activity. Given the severe cognitive adverse events, there is strong need
to optimize anticholinergic drug prescribing in elderly outpatients with dementia.
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OBJECTIVES: To examine the influence of cognitive impairment on functioning,
medical resource utilization, adherence, and health-related quality of life (HRQoL)
in patients with schizophrenia. METHODS: Data analyzed were from a cross-sec-
tional study of patients with schizophrenia and their physicians (2005 Adelphi US
Psychoses XI Disease Specific Programme). Outpatient schizophrenia patients aged
18 years with 4 physician encounters in the past 12 months were identified.
Physicians evaluated their patients’ cognitive impairment, positive and negative
symptoms, functioning (employment status, presence of a caregiver, global assess-
ment of functioning (GAF) scale, Likert scales measuring overall function and abil-
ity to meet own basic needs), adherence, and resource utilization. HRQoL (EQ-5D
tariff and visual analog scale (VAS), Likert scales measuring overall sense of well
being, overall life satisfaction, and satisfaction with relationships) and adherence
data were collected directly from patients. Multivariate analyses were used to ex-
amine the predictors for each outcome variable. Covariates included patients’ de-
mographics and their comorbidities. RESULTS: Eighty one percent of the 839
schizophrenia patients had cognitive impairment. A higher level of cognitive func-
tion was associated with higher overall functioning and GAF scores, improved
ability tomeet basic needs, being employed, not having a caregiver, fewer ER visits,
greatermedication adherence, better HRQoL (EQ-5D and VAS scores), overall sense
of well-being, and higher satisfaction with life and social relationships (p0.05).
The severity of positive and negative symptoms was positively associated with
poorer functioning, number of outpatient visits, and poorer HRQoL. Severe positive
symptoms also predicted more hospitalizations and poorer adherence (p0.05).
Cognitive impairment was associated with fourteen outcomes, while positive and
negative symptoms predicted nine and six outcomes respectively. CONCLUSIONS:
Cognitive impairment in schizophrenia patients is significantly associated with
a number of measures of disease burden, which can substantially increase the
impact of the disease beyond that associated with only positive and negative
symptoms.
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THE BUDGET IMPACT ANALYSIS OF NALTREXONE IN THE TREATMENT OF
ALCOHOL-DEPENDENT PATIENTS IN POLAND
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OBJECTIVES: The purpose was to estimate financial consequences of naltrexone
reimbursement in the treatment of alcohol-dependent patients in Poland.
METHODS: The budget impact analysis was conducted for two-years time horizon
from the public payer perspective (National Health Fund) and, additionally, form
the patient perspective. The target population consisting of the alcohol-dependent
patients, who are treated in dependent treatment centres and are eligible for nal-
trexone therapy was estimated on the basis of epidemiological data and clinical
expert’s opinion. In the analysis two scenarios were compared: present, in which
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